Physician profile
Victor E Corrigan
NPI 1740289446
$113,907.03
in general payments reported to CMS, 2019-2025
31 companies · $2,454 in 2025
The $2,454 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $553 · 2021: $877 · 2022: $618 · 2023: $703 · 2024: $108K · 2025: $2,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $109K · Food and Beverage: $2,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $108,611.28 |
| Food and Beverage | $2,553.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $108,611.28 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $1,039.60 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,033.70 | 2019-2024 | Xarelto |
| Amgen INC. | $370.34 | 2020-2025 | Repatha, Repatha |
| Pfizer INC. | $345.68 | 2019-2025 | |
| Boston Scientific Corporation | $325.81 | 2019-2025 | Varithena Administration Pack, General - Therapies, Synergy |
| Astrazeneca Pharmaceuticals Lp | $317.72 | 2020-2025 | Andexxa, Farxiga |
| Cvrx, INC. | $239.75 | 2024-2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $222.27 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.98 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $189.91 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $155.19 | 2021-2024 | Verquvo |
| Amarin Pharma, INC. | $134.65 | 2019-2020 | |
| Heartflow, INC. | $96.76 | 2022-2025 | Ffrct |
| Medtronic Vascular, INC. | $91.03 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $61.91 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, Ltd. | $61.78 | 2022-2023 | Arcalyst |
| Nuwellis, INC. | $50.83 | 2019 | |
| Sanofi-Aventis U.S. LLC | $50.03 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $49.52 | 2023-2025 | Opsumit, Uptravi |
| Esperion Therapeutics, INC. | $45.33 | 2021-2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $39.77 | 2022-2025 | |
| Saranas, INC. | $34.63 | 2021 | |
| Angiodynamics, INC. | $30.91 | 2021 | |
| Cardiovascular Systems INC. | $22.53 | 2019 | |
| Abiomed | $19.39 | 2024 | Impella |
| Spectrawave, INC | $18.98 | 2025 | Hypervue Imaging System, Starlight Imaging Catheter |
| Baxter Healthcare | $16.40 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Abbott Laboratories | $15.12 | 2020 | |
| Chiesi USA, INC. | $14.23 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$201,389.99 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Corrigan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.